How should we use anti-CTLA-4 antibodies?

被引：7
|
作者：
Marabelle, Aurelien [1 ,2 ]
Eggermont, Alexander [1 ]
机构：
[1] Gustave Roussy Canc Campus Grand Paris, F-94805 Villejuif, France
[2] INSERM, U1015, F-94805 Villejuif, France
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷 / 17期
关键词：
REGULATORY T-CELLS; METASTATIC MELANOMA; IPILIMUMAB;
D O I：
10.1016/j.ejca.2015.09.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2686 / 2688
页数：3
相关论文
共 50 条
  • [31] Role of anti-CTLA-4 therapies in the treatment of cancer
    Abrams, SI
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2004, 6 (01) : 71 - 77
  • [32] Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy
    Pol, Jonathan
    Kroemer, Guido
    CELL RESEARCH, 2018, 28 (05) : 501 - 502
  • [33] Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy
    Sznol, M.
    Melero, I.
    ANNALS OF ONCOLOGY, 2021, 32 (03) : 295 - 297
  • [34] Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy
    Jonathan Pol
    Guido Kroemer
    Cell Research, 2018, 28 : 501 - 502
  • [35] Development and validation of a reporter gene assay to determine the bioactivity of anti-CTLA-4 monoclonal antibodies
    Liu, Chunyu
    Yu, Chuanfei
    Yang, Yalan
    Cui, Yongfei
    Zhang, Feng
    Wang, Lan
    Wang, Junzhi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 101
  • [36] Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety
    Seeruttun, Sharvesh Raj
    AIMS GENETICS, 2019, 6 (03): : 64 - 66
  • [37] Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    Peggs, Karl S.
    Quezada, Sergio A.
    Chambers, Cynthia A.
    Korman, Alan J.
    Allison, James P.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2009, 206 (08): : 1717 - 1725
  • [38] Assessment of pharmacology and toxicology of anti-CTLA-4 antibody (ADU-1604) in nonhuman primates and evaluation of local anti-CTLA-4 application
    Hendriks, Maaike
    Kreijtz, Joost
    Vink, Paul
    Hulsik, David Lutje
    Lodewijks, Imke
    Bertens, Astrid
    van de Crommert, Jos
    Habraken, Maurice
    Janssen, Wout
    Stammen-Vogelzang, Judith
    Gardner, Olivia
    Deng, Weiwen
    Leong, Meredith
    McWhirter, Sarah
    van Eenennaam, Hans
    van Elsas, Andrea
    CANCER RESEARCH, 2018, 78 (13)
  • [39] Colitis induced by immune checkpoint inhibitors: Anti-CTLA-4 antibodies and anti-PD-1/PDL-1 antibodies
    Vozy, A.
    Coutzac, C.
    ONCOLOGIE, 2016, 18 (9-10) : 501 - 508
  • [40] Recurrent malignant melanoma of the uterine cervix treated with anti-PD-1 antibodies and anti-CTLA-4 antibodies: A case report
    Sone, Kenbun
    Kukita, Asako
    Masui, Yuri
    Yamada, Daisuke
    Shinozaki-Ushiku, Aya
    Kawata, Akira
    Taguchi, Ayumi
    Miyamoto, Yuichiro
    Tanikawa, Michihiro
    Iriyama, Takayuki
    Tsuruga, Tetsushi
    Osuga, Yutaka
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (03)
12345